Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 – 17 years

Bibliography

• O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374(9693):893-902
   PubMed Web of Science ®Google Scholar
• Scott JA. The preventable burden of pneumococcal disease in the developing world. Vaccine 2007;25(13):2398-405
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: prevnar 13. US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD; 2011. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf [Cited 24 March 2013]
   Google Scholar
• European Medicines Agency: assessment Report Prevenar 13. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500139411.pdf [Cited 19 March 2013]
   Google Scholar
• Department of Health and Human Services. Statistical Review And Evaluation BLA 125324/767. 2012. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM337688.pdf [Cited 19 March 2013
   Google Scholar
• Laferriere C. The immunogenicity of pneumococcal polysaccharides in infants and children: a meta-regression. Vaccine 2011;29(40):6838-47
   PubMed Web of Science ®Google Scholar
• Licciardi PV, Balloch A, Russell FM, et al. Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol 2012;129(3):794-800; e2
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Westerink MAJ. Novel vaccine strategies to T-independent antigens. J Microbiol Methods 2001;47(2):135-49
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 2003;348(18):1737-46
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19(3):187-95
   PubMed Web of Science ®Google Scholar
• Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25(9):779-81
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344(6):403-9
   PubMed Web of Science ®Google Scholar
• Tocheva AS, Jefferies JMC, Rubery H, et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine 2011;29(26):4400-4
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760-8
   PubMed Web of Science ®Google Scholar
• Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005;192(11):1988-95
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7(10):e1000348
   PubMed Web of Science ®Google Scholar
• Kaye P, Malkani R, Martin S, et al. Invasive Pneumococcal Disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines: Health Protection Agency. 27th annual meeting of the European Society For Paediatric Infectious Diseases (ESPID); Brussels, Belgium; 2009
   Google Scholar
• Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2010;59(11 RR):1-19
   PubMedGoogle Scholar
• Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007;25(19):3816-26
   PubMed Web of Science ®Google Scholar
• Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010;29(12):e80-90
   PubMed Web of Science ®Google Scholar
• Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vacc Immunol 2010;17(6):1017-26
   PubMed Web of Science ®Google Scholar
• Bryant KA, Block SL, Baker SA, et al. Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine. Pediatrics 2010;125(5):866-75
   PubMed Web of Science ®Google Scholar
• WHO/Health Canada Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. 2008. Available from: http://www.who.int/biologicals/publications/meetings/areas/vaccines/pneumococcal/Pneumo Meeting Report FINAL IK 24_Dec_08.pdf [Cited 20 March 2013]
   Google Scholar
• Moore M, Link-Gelles R, Farley M, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010–11. 8th International Symposium on Pneumococci and Pneumococcal Diseases; Brazil; 2012
   Google Scholar
• Link-Gelles R, Taylor T, Moore MR. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010–2020. Vaccine 2013;31(22):2572-7
   PubMed Web of Science ®Google Scholar
• Health Protection Agency. Current Epidemiology of Invasive Pneumococcal Disease (IPD): In Prevenar 13™ Not In Prevenar PCV7. 2013. Available from: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/InPrevenar13NotInPrevenarPCV7 / [Cited 20 March 2013]
   Google Scholar
• Joint Committee on Vaccination and Immunisation: Pneumococcal sub-committee. 2012. Available from: https://http://www.wp.dh.gov.uk/transparency/files/2012/07/JCVI-minutes-Pneumococcal-sub-committee-meeting-held-on-30-May-2012.pdf [Cited 07 February 2013]
   Google Scholar
• Trück J, Lazarus R, Clutterbuck EA, et al. The zwitterionic type I Streptococcus pneumoniae polysaccharide does not induce memory B cell formation in humans. Immunobiology 2013;218(3):368-72
   PubMed Web of Science ®Google Scholar
• Poolman J, Kriz P, Feron C, et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 2009;27(24):3213-22
   PubMed Web of Science ®Google Scholar
• Kim JO, Romero-Steiner S, Sørensen UBS, et al. Relationship between Cell Surface Carbohydrates and Intrastrain Variation on Opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 1999;67(5):2327-33
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294(16):2043-51
   PubMed Web of Science ®Google Scholar
• Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. J Am Med Assoc 2006;295(14):1668-74
   PubMed Web of Science ®Google Scholar
• Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR 2005;54(36):893-7
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Vaccination Schedules. 2013. Available from: http://ecdc.europa.eu/en/activities/surveillance/euvac/schedules/Pages/schedules.aspx [Cited 27 March 2013]
   Google Scholar
• Bennett NM, Whitney CG, Moore M, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61(40):816-19
   PubMedGoogle Scholar
• Department of Health. Green Book: Immunisation against infectious disease. Department of Health; London, UK: 2012
   Google Scholar
• Health Protection Agency: invasive pneumococcal disease incidence rate per 100,000 population by age grouping England and Wales, 1996-2005. 2008. Available from: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/BackgroundEpidemiologyPneumococcal/IPDGraphs/pneumoIPDIncidenceRate/ [Cited 2012]
   Google Scholar
• CDC. Centers for Disease Control and Prevention. 2013. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae. 2011. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu11.html [Cited 21 March 2013]
   Google Scholar
• Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004;363(9424):1871-2
   PubMed Web of Science ®Google Scholar
• Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 2005;133(5):891-8
   PubMed Web of Science ®Google Scholar
• Cardozo DM, Nascimento-Carvalho CM, Andrade A-LSS, et al. Prevalence and risk factors for nasopharyngeal carriage of Streptococcus pneumoniae among adolescents. J Med Microbiol 2008;57(2):185-9
   PubMed Web of Science ®Google Scholar
• Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years. 2011. Available from: http://clinicaltrials.gov/show/NCT00761631 [Cited 2013 27 March 2013]
   Google Scholar
• Frenck Jr R, Thompson A, Yeh SH, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 2011;30(12):1086-91
   PubMed Web of Science ®Google Scholar
• Payton T, Girgenti D, Frenck R, et al. Immunogenicity, safety, and tolerability of three lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States. Pediatr Infect Dis J 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Frenck Jr R, Thompson A, Senders S, et al. 13-valent pneumococcal conjugate vaccine in older children and teens either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. 8th International Symposium on Pneumococci and Pneumococcal Diseases Iguacu Falls; Brazil; 2012
   Google Scholar
• Quinet B, Laudat F, Gurtman A, et al. PCV-elicited antibody persistence and responses to PCV13 in children previously vaccinated with 4 doses of either PCV7 or PCV13. 8th International Symposium on Pneumococci and Pneumococcal Diseases Iguacu Falls; Brazil; 2012
   Google Scholar
• Trück J, Tatangeli F, Snape M, et al. Antibody persistence to pre-school years following immunisation at 2, 4 and 12 months with 7-valent and 13-valent pneumococcal glycoconjugate vaccines. 8th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); Melbourne, Australia; 2011
   Google Scholar
• Trück J, Snape MD, Tatangeli F, et al. Antibody persistence to pre-school years following immunisation at 2, 4 and 12 months with 7-valent and 13-valent pneumococcal glycoconjugate vaccines. 31st annual meeting of the European Society For Paediatric Infectious Diseases; Milan, Italy; 2013
   Google Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24
   PubMed Web of Science ®Google Scholar
• Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008;8(1):67-80
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vacc and Immunother 2012;8(2):161-73
   PubMed Web of Science ®Google Scholar
• King Jr JC, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15(3):192-6
   PubMed Web of Science ®Google Scholar
• Spoulou VI, Tsoumas DL, Papaevangelou VG, et al. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005;23(46–47):5289-93
   PubMed Web of Science ®Google Scholar
• Tarragó D, Casai J, Ruiz-Contreras J, et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005;12(1):165-70
   PubMedGoogle Scholar
• De Montalembert M, Abboud MR, Fiquet A, et al. A 2-dose schedule of 13-valent Pneumococcal Conjugate Vaccine (PCV13) given to children with sickle cell disease previously immunized with 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23): results of a phase 3 study. 54th Annual Meeting of the American Society of Hematology; Atlanta, GA, USA; 2012
   Google Scholar
• Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25(10):920-9
   PubMed Web of Science ®Google Scholar
• Thanee C, Pancharoen C, Likitnukul S, et al. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Vaccine 2011;29(35):5886-91
   PubMed Web of Science ®Google Scholar
• Antin JH, Guinan EC, Avigan D, et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11(3):213-22
   PubMed Web of Science ®Google Scholar
• Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003;101(3):831-6
   PubMed Web of Science ®Google Scholar
• Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007;109(6):2322-6
   PubMed Web of Science ®Google Scholar
• Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009;28(8):688-92
   PubMed Web of Science ®Google Scholar
• Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007;25(13):2451-7
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341-8
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, et al. A TRIAL of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362(9):812-22
   PubMed Web of Science ®Google Scholar
• Muhammad RD, Oza-Frank R, Zell E, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis 2013;56(5):e59-67
   PubMedGoogle Scholar
• Remberger M, Ackefors M, Berglund S, et al. Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. Biol Blood Marrow Transplant 2011;17(11):1688-97
   PubMed Web of Science ®Google Scholar
• HRSA. OPTN/SRTR Annual Report: one Year Adjusted Patient Survival by Organ and Year of Transplant, 1998 to 2007. 2009. Available from: http://optn.transplant.hrsa.gov/ar2009/112a_dh.htm [Cited 30 March 2013]
   Google Scholar
• Rozenbaum MH, Van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: Economic analysis. BMJ (Online) 2012;345:7882
   Google Scholar
• Lu CL, Hung CC, Chuang YC, et al. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. Hum Vacc Immunother 2013;9(2):398-404
   PubMed Web of Science ®Google Scholar
• Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998;133(2):275-8
   PubMed Web of Science ®Google Scholar
• Smets F, Bourgois A, Vermylen C, et al. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Vaccine 2007;25(29):5278-82
   PubMed Web of Science ®Google Scholar
• Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011;52(6):736-42
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9):1318-25
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007;7(9):597-606
   PubMed Web of Science ®Google Scholar
• Borrow R, Heath PT, Siegrist CA. Use of pneumococcal polysaccharide vaccine in children: what is the evidence? Curr Opin Infect Dis 2012;25(3):292-303
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008(1):CD000422
   PubMed Web of Science ®Google Scholar
• Trück J, Lazarus R, Jonsdottir I, et al. Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present. Clin Infect Dis 2012;55(11):1577-9
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012;30(48):6802-8
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19(3):187-95
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Satzke C, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vacc Immunol 2010;17(12):1970-6
   PubMed Web of Science ®Google Scholar
• Hsu KK, Shea KM, Stevenson AE, et al. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010;29(4):289-93
   PubMed Web of Science ®Google Scholar
• Hanage WP, Finkelstein JA, Huang SS, et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2010;2(2):80-4
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367(9512):740-8
   PubMed Web of Science ®Google Scholar
• Ogunniyi AD, Grabowicz M, Briles DE, et al. Development of a Vaccine against Invasive Pneumococcal Disease Based on Combinations of Virulence Proteins of Streptococcus pneumoniae. Infect Immun 2007;75(1):350-7
   PubMed Web of Science ®Google Scholar
• Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006;32(3):139-53
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. 31st annual meeting of the European Society for Paediatric Infectious Diseases; Milan, Italy; 2013
   Google Scholar
• Vieira S, Baldacci E, Carneiro-Sampaio M, et al. Evaluation of antibody response to the heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease. Pediatr Nephrol 2009;24(1):83-9
   PubMed Web of Science ®Google Scholar
• Mikoluc B, Kayhty H, Bernatowska E, et al. Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children. Eur J Clin Microbiol Infect Dis 2008;27(10):923-8
   PubMed Web of Science ®Google Scholar
• Forstner C, Plefka S, Tobudic S, et al. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. Vaccine 2012;30(37):5449-52
   PubMed Web of Science ®Google Scholar
• Cheng FWT, Ip M, Chu YYL, et al. Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients. Arch Dis Child 2012;97(4):358-60
   PubMed Web of Science ®Google Scholar
• Pao M, Papadopoulos EB, Chou J, et al. Response to Pneumococcal (PNCRM7) and Haemophilus Influenzae Conjugate Vaccines (HIB) in Pediatric and Adult Recipients of an Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biol Blood Marrow Transplant 2008;14(9):1022-30
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Brinson CC, Greenberg RN, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV+ adults with prior 23-valent pneumococcal polysaccharide vaccination. 20th Conference on Retroviruses and Opportunistic Infections (CROI); Atlanta, GA, USA; 2013
   Google Scholar